Navigation Link

1215 South Walnut Ave.
Demopolis, AL 36732 map map 

Access to Care: 1-800-239-2901

1215 South Walnut Ave.
Demopolis, AL 36732
334.289.2416 (fax)

powered by centersite dot net
Aging & Geriatrics
Basic InformationLatest News
'Mild Cognitive Impairment' in Older Age Often Disappears, Study FindsReminder Apps on Smartphones May Help in Early DementiaNeurologists' Group Issues Guidance to Families on Controversial Alzheimer's DrugTrial Begins of Nasal Vaccine for Alzheimer's DiseaseGrandmother's Brain In Sync With Her Grandkids': StudyAlzheimer's Diagnosis May Come With Big Cost to Social LifeAlmost 1 in 3 U.S. Seniors Now Sees at Least 5 Doctors Per YearLanguage Can Make the Difference Between Home, Hospital Care: StudyRight Amount of Sleep May Be Important in Early Alzheimer'sAHA News: Hearing Loss and the Link to DementiaFDA Eases Access to Cheaper Over-the-Counter Hearing AidsAfter an ICU Stay, Social Support Crucial for Seniors' SurvivalCould Cheaper, Over-the-Counter Hearing Aids Finally Be Here?AHA News: What Are Researchers Doing to Stop Dementia?Having Someone Who'll Listen May Be Good for Your Aging BrainA Second 'Closet' for Some LGBTQ Seniors Entering Nursing HomesDeaths From Alzheimer's Far More Common in Rural America1 in 20 Cases of Dementia Occurs in People Under 65Reading, Puzzles May Delay Alzheimer's by 5 Years: StudyMedicare Mulls Coverage for Controversial Alzheimer's DrugMissing Teeth, Higher Odds for Dementia?Healthy Living Can Lower Your Odds for Alzheimer'sMost Cases of Dementia in U.S. Seniors Go Undiagnosed: StudyHealthy Living Helps Prevent Dementia, Even If It Runs in the FamilyAHA News: Is It Normal Aging or Early Signs of Dementia?Do Prescription Sleep Medicines Even Work?Lullaby Effect: Music Can Speed Your Way to Sleep, Study Finds4 in 10 Adults Over 50 Consult Online Reviews When Picking a DoctorLoneliness in Mid-Life Linked to Higher Odds for Alzheimer'sDrug Used in Cancer Patients Might Help Treat Alzheimer'sAlzheimer's Patients Are Being Given Too Many MedsAlzheimer's May Strike Women and Men in Different WaysAHA News: Black, Hispanic Families Hit Hardest by DementiaWhy Some 'Super Ager' Folks Keep Their Minds Dementia-FreeToo Little Sleep Could Raise Your Dementia RiskAphasia Affects Brain Similar to Alzheimer's, But Without Memory LossHome-Based Care Teams Offer Help for Those With Dementia
Questions and AnswersVideosLinksBook ReviewsSelf-Help Groups
Related Topics

Depression: Depression & Related Conditions
Elder Care

Neurologists' Group Issues Guidance to Families on Controversial Alzheimer's Drug

HealthDay News
by Robert Preidt
Updated: Nov 18th 2021

new article illustration

THURSDAY, Nov. 18, 2021 (HealthDay News) -- Neurologists must make sure Alzheimer's patients and their families understand that the controversial drug aducanumab does not restore mental function, the American Academy of Neurology (AAN) said in new position statement that includes ethical guidelines.

"Aducanumab is not a cure for Alzheimer's disease, yet since it has been approved by the [U.S. Food and Drug Administration], patients are asking their doctors if this is an option for them," said statement author Dr. Winston Chiong, an associate professor at the University of California San Francisco and member of the AAN's Ethics, Law and Humanities Committee.

"This is a high-cost drug that was approved by the FDA without convincing evidence of benefits and with known harms, so the purpose of this position statement is to offer ethical guidance on how neurologists can help patients make informed decisions about this treatment," Chiong said in an AAN news release.

The U.S. Food and Drug Administration approved aducanumab (brand name: Aduhelm) based on two studies that were both stopped early because the drug showed no benefits for patients. The statement explained that a later analysis of data from one of those studies suggested a small benefit, while the other still showed no benefit.

The statement noted that while aducanumab reduces the beta-amyloid plaques in the brain that are markers of Alzheimer's, it's unclear whether that provides any meaningful benefits to patients.

There isn't sufficient evidence to offer the drug to patients with moderate or advanced dementia, or to those without evidence of beta-amyloid in the brain, according to the position statement published Nov. 17 in the journal Neurology.

It also said the drug carries a risk of brain inflammation and brain bleeds, which occurred in a third of patients in the studies who received the dose approved by the FDA.

The statement said neurologists must inform patients and families about the drug's potential risks of and the need for more frequent monitoring with MRI scans.

Another issue is the lack of racial and ethnic diversity in the clinical trials of aducanumab. Patients in racial and ethnic minorities need to be told about the lack of safety and effectiveness data for them, the statement said.

In addition, it warned that pricing and insurance coverage of the drug may cause financial harm to patients and their families.

Aducanumab is priced at $56,000 a year. But the costs of infusing the drug, repeated imaging and medical management may push annual costs to more than $100,000. Medicare generally covers 80%, so patients and families must be told that the full cost of treatment may not be covered, the statement advised.

The statement said another concern is that availability of aducanumab may lead to lower patient enrollment in clinical trials of more effective treatments.

More information

The U.S. National Institute on Aging has more about Alzheimer's disease treatment.

SOURCE: American Academy of Neurology, news release, Nov. 17, 2021